PDCD1 and non-small cell lung carcinoma: Consistent with these suggestions, our analysis, showed that PD-L1expression cutoff of 10% was sufficient to display the advantage of choosing PD-1/PD-L1 antibody therapy in NSCLC over standard second line chemotherapy, docetaxel.